https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52704 Wed 28 Feb 2024 16:34:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34079 Wed 17 Nov 2021 16:31:48 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44371 Wed 12 Oct 2022 11:07:39 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:15739 Wed 11 Apr 2018 11:30:37 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43929 Wed 05 Oct 2022 12:37:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30811 12 weeks post-treatment). Results: Among 93 people treated, 59% had recently injected drugs (past month), 77% were receiving OST and 56% injected drugs during therapy. Overall, 76% completed treatment. Mean on-treatment adherence to PEG-IFN and ribavirin were 98.2% and 94.6%. Overall, 6% of participants missed >1 dose of PEG-IFN and 31% took <95% of their prescribed ribavirin., Higher treatment completion was observed among those receiving 12 vs. 24 weeks of treatment (97% vs. 46%, P < 0.001) while the proportion of participants with 95% on-treatment ribavirin adherence was similar between groups (67% vs. 72%, P = 0.664). Receiving 12 weeks of therapy was independently associated with treatment completion. No factors were associated with 95% RBV adherence. Neither recent injecting drug use at baseline nor during therapy was associated with treatment completion or adherence to ribavirin. In adjusted analysis, treatment completion was associated with SVR (aOR 23.9, 95% CI 2.9–193.8). Conclusions: This study demonstrated a high adherence to directly observed PEG-IFN and self-administered ribavirin among people with ongoing injecting drug use or receiving OST. These data also suggest that shortening therapy from 24 to 12 weeks can lead to improved treatment completion. Treatment completion was associated with improved response to therapy.]]> Thu 28 Oct 2021 13:03:33 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51850 Thu 21 Sep 2023 09:34:33 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:17729 Sat 24 Mar 2018 07:57:45 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49510 Fri 19 May 2023 16:56:03 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43014 Fri 09 Sep 2022 16:16:22 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34078 12 weeks post-treatment). Results: Among 93 people with ongoing injecting drug use or receiving OST treated for HCV genotype 2/3, 59% had recently (past month) injected drugs, 77% were receiving OST and 56% injected drugs during therapy. Overall SVR was 66% (61/93). SVR was 84% in those with undetectable HCV RNA at week 4 (12 weeks) compared to 38% in those without (24 weeks). In adjusted analysis, cirrhosis vs. no/mild fibrosis [adjusted OR (aOR) 0.33, 95% CI 0.13, 0.86] predicted reduced SVR, while response at week 4 was associated with increased SVR [aOR 8.11, 95% CI 2.73, 24.10] . Recent injecting drug use at baseline or during therapy was not associated with SVR. Conclusion: This study demonstrates that people with recent injecting drug use or OST with chronic HCV can achieve responses to interferon-based therapy similar to other populations, despite injecting drugs prior to or during therapy. Cirrhosis was predictive of reduced response to HCV therapy, while response at week 4 (despite shortened therapy) was predictive of improved response.]]> Fri 03 Dec 2021 10:35:13 AEDT ]]>